Ascendis Pharma Q2 FY26 swings to net profit of €207 million; revenue more than doubles to €339 million

Reuters2026/08/13 11:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ascendis Pharma posted Q2 2026 revenue of EUR 339 million, more than doubled year over year, with product revenue up 105% to EUR 315 million.
IFRS net profit swung to EUR 207 million, or EUR 2.83 per diluted share, from a loss a year earlier.
IFRS operating profit turned to EUR 220 million, helped by EUR 158 million of other operating income from a PRV sale.
YORVIPATH revenue climbed to EUR 252 million, while SKYTROFA generated EUR 55 million; YUVIWEL contributed EUR 8 million.
Management cited strong demand for TransCon products; YUVIWEL topped 220 U.S. patient enrollments through July 31.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130730PRIMZONEFULLFEED9809465) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ascendis Pharma Q2 FY26 swings to net profit of €207 million; revenue more than doubles to €339 million

You may also like

Crypto prices